Jacobs M R, Spangler S K, Appelbaum P C
Institute of Pathology, Case Western Reserve University, Cleveland, Ohio.
Eur J Clin Microbiol Infect Dis. 1992 Nov;11(11):1081-93. doi: 10.1007/BF01967803.
The susceptibility of 1,476 US and European strains of anaerobic gram-negative bacilli to amoxicillin, amoxicillin/clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem and metronidazole was determined. All of the Bacteroides fragilis group and 51% of the non-Bacteroides fragilis group were beta-lactamase positive. Amongst the non-Bacteroides fragilis group, beta-lactamase positivity rates were higher for US strains (58%) than for European strains (39%). All strains were susceptible to imipenem and metronidazole. MIC90s of amoxicillin and ticarcillin for all beta-lactamase negative strains were 0.5 and 2 micrograms/ml, respectively. The addition of clavulanate reduced the MIC90s of amoxicillin (> or = 256 micrograms/ml) and ticarcillin (> or = 64 micrograms/ml) to 16 and 8 micrograms/ml, respectively, for the Bacteroides fragilis group, and to 4 micrograms/ml for both agents for the non-Bacteroides fragilis beta-lactamase producing group. Twenty-nine cefoxitin-resistant strains were found, mainly in the Bacteroides fragilis group, while 95 beta-lactamase producing strains (predominantly Bacteroides fragilis group and fusobacteria) did not show synergy between beta-lactams and clavulanate. Of the newe agents tested, meropenem and piperacillin-tazobactam were the most active (100% of strains susceptible), followed by amoxicillin-BRL 42715 (99% of strains susceptible); 94 to 98% of the strains were susceptible to cefoperazone-sulbactam, tosufloxacin, temafloxacin and clindamycin. Only 73% of the strains were susceptible to cefotetan, compared to 91% to cefoxitin; 88% of the strains were susceptible to trospectomycin. Overall, all of the beta-lactam/beta-lactamase inhibitor combinations, imipenem, meropenem, cefoxitin, tosufloxacin, temafloxacin and clindamycin had good activity against beta-lactamase producing strains, while all agents tested had good activity against beta-lactamase negative strains.
测定了1476株美国和欧洲的厌氧革兰氏阴性杆菌对阿莫西林、阿莫西林/克拉维酸、替卡西林、替卡西林/克拉维酸、头孢西丁、亚胺培南和甲硝唑的敏感性。所有脆弱拟杆菌群和51%的非脆弱拟杆菌群为β-内酰胺酶阳性。在非脆弱拟杆菌群中,美国菌株的β-内酰胺酶阳性率(58%)高于欧洲菌株(39%)。所有菌株对亚胺培南和甲硝唑敏感。所有β-内酰胺酶阴性菌株对阿莫西林和替卡西林的MIC90分别为0.5和2微克/毫升。加入克拉维酸后,对于脆弱拟杆菌群,阿莫西林(≥256微克/毫升)和替卡西林(≥64微克/毫升)的MIC90分别降至16和8微克/毫升,对于非脆弱拟杆菌β-内酰胺酶产生群,两种药物的MIC90均降至4微克/毫升。发现29株头孢西丁耐药菌株,主要在脆弱拟杆菌群中,而95株β-内酰胺酶产生菌株(主要是脆弱拟杆菌群和梭杆菌)在β-内酰胺类药物和克拉维酸之间未显示协同作用。在所测试的新药中,美罗培南和哌拉西林-他唑巴坦活性最强(100%的菌株敏感),其次是阿莫西林-BRL 42715(99%的菌株敏感);94%至98%的菌株对头孢哌酮-舒巴坦、妥舒沙星、替马沙星和克林霉素敏感。只有73%的菌株对头孢替坦敏感,而对头孢西丁的敏感率为91%;88%的菌株对大观霉素敏感。总体而言,所有β-内酰胺/β-内酰胺酶抑制剂组合、亚胺培南、美罗培南、头孢西丁、妥舒沙星、替马沙星和克林霉素对β-内酰胺酶产生菌株具有良好活性,而所有测试药物对β-内酰胺酶阴性菌株均具有良好活性。